U.S. cannabis stocks experienced a broad rally this week, fueled by renewed policy signals from President Donald Trump. In a video posted on Truth Social on Sunday, Trump advocated for including CBD (cannabidiol) derived from hemp in the coverage of federal Medicare, emphasizing its potential benefits for seniors in managing pain, reducing stress, and improving sleep.
This marks the second positive signal for the industry from Trump in recent weeks. He previously indicated he was considering supporting the federal reclassification of cannabis, which remains a Schedule I controlled substance under federal law.
The prospect of regulatory easing sparked significant buying interest in major cannabis producers:
It’s worth noting that while CGC and CRON have since retreated to their pre-surge price levels, TLRY and ACB have managed to hold on to most of their gains.
According to Grand View Research, the U.S. cannabis market is projected to grow from $38.5 billion in 2024 to $74.0 billion by 2030, representing a compound annual growth rate (CAGR) of 11.51%. However, investing directly in individual cannabis companies carries high risks. Most have relatively small market capitalizations (e.g., Aurora Cannabis at approximately $329 million) and their stocks are notoriously volatile.
For retail investors, thematic Exchange-Traded Funds (ETFs) might offer a more diversified and potentially less risky approach:
Despite the recent policy tailwinds, cannabis remains illegal at the federal level in the United States. Many companies in the sector also have weak financial foundations. Investors should be fully aware of the high-risk nature of this industry. A diversified approach through ETFs is often recommended to navigate the potential opportunities while mitigating company-specific risks.
